Evgen Pharma plc

("Evgen", the "Company" or the "Group")

Change of Name

and

Change of Company Website

Alderley Park, UK - 25 April 2024: Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, confirms that further to its announcement on 19 March 2024, the Company's change of name to TheraCryf plc and change of AIM ticker to TCF will become effective tomorrow, 26 April 2024.

At the same time the Company notifies shareholders that, pursuant to AIM Rule 26, its corporate website will also change to www.theracryf.com effective tomorrow.

- Ends -

Enquiries

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead clinical asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands funded by a grant from the Netherlands government and Dutch Cancer Society.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

Evgen recently acquired neuropsychiatry company Chronos Therapeutics Limited, now a wholly owned affiliate of the Company The acquired assets comprise an orexin-1 antagonist (Ox-1) in late pre-clinical development targeting impulsivity and anxiety disorders and an atypical dopamine transporter inhibitor (DAT) also in late pre-clinical development for fatigue, e.g. due to long COVID or multiple sclerosis and the orphan condition narcolepsy.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com.